Two injections, two different jobs in the hip

Patients with hip cartilage wear are sometimes offered two injections that sound similar but work in fundamentally different ways: hyaluronic acid (HA) viscosupplementation and ChondroFiller injection. Choosing between them is less about preference and more about where your hip sits on the spectrum of cartilage loss.

HA viscosupplementation replenishes and restores the lubricating properties of synovial fluid. It is suited to mild-to-moderate hip osteoarthritis, where the joint still has enough cartilage surface to benefit from improved lubrication. ChondroFiller injection takes a different approach altogether — it delivers an injectable collagen scaffold that coats worn articular surfaces and recruits the body's own repair cells, making it the more appropriate option for patients with advanced, diffuse cartilage wear where lubrication alone is no longer sufficient.

The Kellgren-Lawrence (KL) grading scale — a standard radiographic measure of osteoarthritis severity — is the clinical compass that helps determine which rung of the pre-surgical hierarchy a patient occupies. Both injections are outpatient, ultrasound-guided procedures given under local anaesthesia; neither requires a general anaesthetic or an operating theatre. The shared aim is to delay or avoid hip replacement, not to substitute for it indefinitely.

How hyaluronic acid works in the hip joint

Inside a healthy hip joint, hyaluronic acid (HA) is a key constituent of synovial fluid, contributing both viscosity and lubrication. In osteoarthritis, the concentration and molecular weight of endogenous HA fall, leaving joint fluid thinner and less protective. Intra-articular HA injection aims to restore that mechanical environment — not to repair cartilage, but to improve the conditions in which worn surfaces move against each other. The effect is symptomatic rather than structural; HA does not promote cartilage regeneration.

The hip-specific trial evidence is reasonably well-established. Qvistgaard and colleagues (2006) compared HA against corticosteroid and isotonic saline in a randomised trial of hip osteoarthritis, with HA outperforming the saline control for symptom relief. Spitzer and colleagues demonstrated functional improvement with Hylan G-F 20 — a cross-linked, high-molecular-weight preparation — in a prospective RCT. Clementi and colleagues found that even a single ultra-high molecular weight injection produced meaningful benefit in hip OA, a practically useful finding given the depth and technical demands of hip delivery. The clearest signal on formulation comes from De Lucia and colleagues (Frontiers in Pharmacology, 2019): patients receiving repeated courses of high-molecular-weight HA achieved better outcomes than those on medium-molecular-weight HA, suggesting that product selection has real clinical consequences, not merely theoretical ones.

High-MW preparations resist enzymatic degradation more effectively in vivo and more closely approximate native synovial fluid composition. Ultrasound guidance is standard given the hip joint's anatomical depth, and repeat courses are feasible where the initial response is meaningful.

The typical candidate for HA viscosupplementation has mild-to-moderate hip OA with joint space still visible on imaging and is seeking durable symptomatic relief rather than structural cartilage repair.

What ChondroFiller injection does differently

The distinction separating ChondroFiller injection from HA viscosupplementation is biological rather than procedural. Both are outpatient, ultrasound-guided procedures — but where HA restores the mechanical environment around cartilage, ChondroFiller provides a structural scaffold within it.

ChondroFiller® liquid is an acellular Type I collagen gel, classified as a Class III medical device, that gels in situ once placed into the hip joint. The mechanism is matrix-induced chondrogenesis: the scaffold creates a chemotactic matrix that recruits the patient's own progenitor cells to migrate in and initiate endogenous repair. No exogenous cells or growth factors are introduced — the collagen framework organises the body's own repair response. This is a fundamentally different biological intent from viscosupplementation, which provides lubrication but does not initiate tissue-level repair.

The clinical target reflects this intent. ChondroFiller injection is designed for more advanced, diffuse hip cartilage wear — Kellgren-Lawrence Grade III or IV — where worn articular surfaces need structural support beyond lubrication. Applied as a top-down coating over those surfaces, the scaffold cushions from above rather than rebuilding from the subchondral bone upwards. ChondroFiller was historically used as an arthroscopic surgical implant placed into debrided focal defects under dry-field conditions; as an injection, it addresses the broader, diffuse wear pattern more typical of advanced hip osteoarthritis.

Published outcome data are more extensive in the knee, where IKDC scores improve by approximately 30 points over 12 months and MOCART MRI scores of 70–87 have been reported in clinical investigations. For hip patients, the modified Harris Hip Score is the primary functional measure, with similar-magnitude gains described at 12 months.

How Kellgren-Lawrence grade shapes the decision

Radiographic grading provides the clearest practical framework for matching a patient to the right injection. The Kellgren-Lawrence (KL) scale classifies hip osteoarthritis severity from Grade I — minor osteophytes and doubtful joint space narrowing — through to Grade IV, where large osteophytes, severe joint space loss, and bony deformity are visible on plain X-ray. Each grade band points toward a different injection strategy.

At KL Grade I or II, joint space is still present and meaningful, making HA viscosupplementation the logical first-line intervention. Lubrication adds real benefit where surfaces can still be protected; PRP may be considered alongside HA as an adjunct at this stage.

At KL Grade III or IV, diffuse surface degradation has progressed beyond what lubrication alone can usefully address. ChondroFiller injection — a collagen scaffold that coats worn articular surfaces and recruits host repair cells — is better positioned for these patients. Where KL Grade IV wear is very advanced and cartilage regeneration is unlikely, Arthrosamid (a permanent hydrogel cushion) may be more appropriate than a regenerative scaffold.

No published, hip-specific randomised controlled trial has directly compared ChondroFiller injection against HA head-to-head. The grade-based hierarchy above reflects clinician-led protocol and clinical experience rather than a mandate from published NICE guidance on hip OA. MRI can supplement plain X-ray grading where characterising cartilage thickness or identifying discrete focal defects would further inform patient selection.

The full pre-surgical injection ladder for hip cartilage wear

Biological intent is what separates these four options — and intent determines sequence. PRP, positioned at the earliest stage for mild hip cartilage wear or used alongside HA, works through anti-inflammatory and early healing signalling rather than mechanical support. HA lubricates. ChondroFiller injection scaffolds and recruits. Arthrosamid — a permanent polyacrylamide hydrogel — cushions without any regenerative aim, making it the fourth rung for hips where cartilage is too depleted for a scaffold to find purchase.

Arthrosamid is the one rung not yet discussed: a single, long-lasting hydrogel injection that integrates into the synovium and acts as a mechanical buffer rather than a biological repair agent. It does not promote tissue regrowth, and it is not interchangeable with ChondroFiller injection. The two sit on different rungs precisely because they do different jobs — one recruits, the other cushions.

None of these four options is appropriate for every hip, and they are not interchangeable steps on an arbitrary ladder. Where the hip is truly end-stage and conservative and injection measures have been exhausted, hip replacement remains the correct next step — and being realistic about that point is part of sound clinical planning.

What to expect from each injection at Lincolnshire Hip

Both injections are delivered as outpatient procedures under ultrasound guidance, with local anaesthesia — no theatre, no overnight stay, and no formal rehabilitation programme attached to either.

The practical differences lie in course structure. HA viscosupplementation is repeatable: depending on the product and molecular weight chosen, patients may return for further courses, and hip OA studies — including De Lucia et al. (2019) — suggest high-molecular-weight formulations offer the most sustained benefit across repeat treatments. ChondroFiller injection is a single-session procedure, priced at £2,995 at Lincolnshire Hip, and carries no surgical recovery burden.

For patients still working out which option fits their Kellgren-Lawrence grade and symptoms, the most useful next step is a structured hip assessment — one that combines imaging review with a clear, unhurried discussion of what each injection is and is not realistically likely to achieve for that specific joint. The decision turns on biology as much as logistics: lubrication or scaffolding, symptomatic relief or structural support.

Lincolnshire Hip is part of the MSK Doctors group, with clinics in Sleaford and Grantham, and accepts patients without referral for hip assessment.